The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Casadevall, N., Nataf, J., Viron, B., Kolta, A., Kiladjian, J.-J., Martin-Dupont, P., Michaud, P., Papo, T., Ugo, V., Teyssandier, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011931 · Cited by 1,246
Berson, S. A., Yalow, R. S., Bauman, A., Rothschild, M. A., & Newerly, K. (1956) · Journal of Clinical Investigation · doi:10.1172/jci103262 · Cited by 836
Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, J., Yang, C., Xia, Y., Bertino, A., Glaspy, J., Roberts, M., & Kuter, D. J. (2001) · Blood · doi:10.1182/blood.v98.12.3241 · Cited by 683
Mire-Sluis, A. R., Barrett, Y. C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., et al. (2004) · Journal of Immunological Methods · doi:10.1016/j.jim.2004.06.002 · Cited by 624
Self-citationImmunogenicity of therapeutic proteins: Clinical implications and future prospects
Schellekens, H. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80075-3 · Cited by 556
Bioequivalence and the immunogenicity of biopharmaceuticals
Schellekens, H. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd818 · Cited by 534
Factors influencing the immunogenicity of therapeutic proteins
Schellekens, H. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh1092 · Cited by 332
Allergic Reactions to Drugs and Biologic Agents
deShazo, R. D. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550220101014 · Cited by 227
ANTI-IDIOTYPIC AND NON-ANTI-INDIOTYPIC ANTIBODIES TO OKT3 ARISING DESPITE INTENSE IMMUNOSUPPRESSION
Jaffers, G. J., Fuller, T. C., Cosimi, A. B., Russell, P. S., Winn, H. J., & Colvin, R. B. (1986) · Transplantation · doi:10.1097/00007890-198605000-00004 · Cited by 185
Scientific and regulatory considerations on the immunogenicity of biologics
Shankar, G., Shores, E., Wagner, C., & Mire-Sluis, A. (2006) · Trends in Biotechnology · doi:10.1016/j.tibtech.2006.04.001 · Cited by 175
Self-citationImmunogenicity of recombinant human proteins: causes and consequences
Schellekens, H., & Casadevall, N. (2004) · Journal of Neurology · doi:10.1007/s00415-004-1202-9 · Cited by 158
Monoclonal antibodies, immunogenicity, and associated infusion reactions.
Cheifetz, A. S., & Mayer, L. (2005) · PubMed · Cited by 152
Klee, G. G. (2000) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2000-124-0921-hama · Cited by 152
Immunogenicity of therapeutic proteins
Schellekens, H. (2003) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfg164 · Cited by 148
Immunogenicity of therapeutic monoclonal antibodies.
Pendley, C. E., Schantz, A., & Wagner, C. (2003) · PubMed · Cited by 147
Self-citationBugelski, P. J., & Treacy, G. (2004) · PubMed · Cited by 130
Goldstein, G., Fuccello, A. J., Norman, D. J., et al. (1986) · Transplantation · doi:10.1097/00007890-198611000-00013 · Cited by 124
Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab)
D'Arcy, C. A., & Mannik, M. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200107)44:7<1717::aid-art299>3.0.co;2-c · Cited by 96
Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe Disease
Hunley, T. E., Corzo, D., Dudek, M. E., Kishnani, P. S., Amalfitano, A., Chen, Y.-T., Richards, S. M., Phillips, J. A., Fogo, A. B., & Tiller, G. E. (2004) · PEDIATRICS · doi:10.1542/peds.2003-0988-l · Cited by 95
O’Mahony, D., & Bishop, M. R. (2006) · Frontiers in bioscience · doi:10.2741/1909 · Cited by 77
Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B
Dharnidharka, V. R., Takemoto, C., Ewenstein, B. M., Rosen, S., & Harris, H. W. (1998) · Pediatric Nephrology · doi:10.1007/s004670050522 · Cited by 28
Dale, D. C., Nichol, J. L., Rich, D. A., Best, D. M., Slichter, S. J., Sheridan, W. P., & Hunt, P. (1997) · Blood · doi:10.1182/blood.v90.9.3456 · Cited by 25
Immunogenicity of xenopeptide hormone therapies
Schnabel, C. A., Fineberg, S. E., & Kim, D. D. H. (2006) · Peptides · doi:10.1016/j.peptides.2006.01.019 · Cited by 24
Cited by
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
Zhang, P., Sun, F., Liu, S., & Jiang, S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.040 · Cited by 688
Shankar, G., Devanarayan, V., Amaravadi, L., Barrett, Y. C., Bowsher, R., Finco-Kent, D., Fiscella, M., Gorovits, B., Kirschner, S., Moxness, M., et al. (2008) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2008.09.020 · Cited by 613
Self-citationThe determination and interpretation of the therapeutic index in drug development
Muller, P. Y., & Milton, M. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3801 · Cited by 563
Recent advances in (therapeutic protein) drug development
Lagassé, H. A. D., Alexaki, A., Simhadri, V. L., Katagiri, N. H., Jankowski, W., Sauna, Z. E., & Kimchi-Sarfaty, C. (2017) · F1000Research · doi:10.12688/f1000research.9970.1 · Cited by 481
Metadata
- Authors
- Shankar, G., Pendley, C., & Stein, K. E.
- Venue
- Nature Biotechnology
- Published
- 2007-05
- Volume
- 25
- Issue
- 5
- Pages
- 555-561
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2012027479
- Cited by
- 260
- References
- 23
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.